Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer

2021 ◽  
Vol 96 (3) ◽  
pp. 592-600 ◽  
Author(s):  
Jiasheng Wang ◽  
Yeseong D. Kim ◽  
Chang H. Kim
Keyword(s):  
Arterial Thromboembolism ◽  
Patients With Cancer

scholarly journals Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Blood ◽  
2020 ◽  
Author(s):  
Florian Moik ◽  
Wei-Shin Evelyn Chan ◽  
Sarah Wiedemann ◽  
Christoph Hoeller ◽  
Felix Tuchmann ◽  
...  
Keyword(s):  
Risk Factors ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Checkpoint Inhibitors ◽  
Hazard Ratio ◽  
Arterial Thromboembolism ◽  
Patients With Cancer ◽  
Checkpoint Inhibitor Therapy

The risk of venous and arterial thromboembolism (VTE/ATE) associated with immune checkpoint inhibitors is currently unclear, and clinical trials evaluating these agents in patients with cancer did not provide information. Our aim was to quantify risk of VTE/ATE in a cohort of patients treated with immune checkpoint inhibitors, explore clinical impact, and investigate potential clinical risk factors. Patients treated with an immune checkpoint inhibitor at the Medical University of Vienna from 2015-2018 were identified using the in-house pharmacy records (n=672; most frequent entities: 30.4% melanoma, 24.1% non-small-cell lung cancer; 86% stage-IV-disease). A retrospective chart-review was performed to screen for VTE and/or ATE. Cumulative incidences and between-group differences were analysed within a competing-risk framework. Multi-state modelling was applied to study the impact of VTE/ATE on mortality. Over a median follow-up of 8.5 months, 47 VTE and 9 ATE were observed. Cumulative incidences of VTE and ATE were 12.9% [95% confidence interval (CI): 8.2-18.5)] and 1.8% [95%CI: 0.7-3.6]. Occurrence of VTE was associated with increased mortality (transition hazard-ratio (THR): 3.09 [95%CI: 2.07-4.60]. History of VTE predicted VTE occurrence (subdistribution hazard ratio (SHR): 3.69 [2.00-6.81]) and distant metastasis was non-significantly associated with VTE risk (SHR: 1.71 [95%CI: 0.62-4.73]). No association of VTE with ECOG performance-status, Charlson-Comorbidity-Index or the Khorana-score was observed, and rates of VTE were comparable among subgroups of tumour types and checkpoint-inhibitory agents. In conclusion, patients with cancer under immune checkpoint inhibitor therapy are at high risk of thromboembolism, especially VTE. Furthermore, VTE occurrence was associated with increased risk of mortality.

scholarly journals Association of complete blood count parameters, d‐dimer, and soluble P‐selectin with risk of arterial thromboembolism in patients with cancer

2019 ◽  
Vol 17 (8) ◽  
pp. 1335-1344 ◽  
Author(s):  
Ella Grilz ◽  
Christine Marosi ◽  
Oliver Königsbrügge ◽  
Julia Riedl ◽  
Florian Posch ◽  
...  
Keyword(s):  
Blood Count ◽  
Complete Blood Count ◽  
Arterial Thromboembolism ◽  
Patients With Cancer ◽  
Soluble P ◽  
D Dimer

scholarly journals Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer

Haematologica ◽  
2018 ◽  
Vol 103 (9) ◽  
pp. 1549-1556 ◽  
Author(s):  
Ella Grilz ◽  
Oliver Königsbrügge ◽  
Florian Posch ◽  
Manuela Schmidinger ◽  
Robert Pirker ◽  
...  
Keyword(s):  
Risk Factors ◽  
Arterial Thromboembolism ◽  
Patients With Cancer

scholarly journals Risk of Arterial and Venous Thromboembolic Events with Bevacizumab, an Antibody against Vascular Endothelial Growth Factor A (VEGF-A): A Systematic Review and Meta-Analysis

2020 ◽  
pp. 71-85
Author(s):  
Mihika Ashish Shah ◽  
Mandar Kalpesh Shah ◽  
Sharan Dharmesh Shah ◽  
Harshil Devang Patel ◽  
Parshwa Keyur Shah ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Meta Analysis ◽  
Vascular Endothelial ◽  
Arterial Thromboembolism ◽  
Patients With Cancer ◽  
Humanized Monoclonal Antibody ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Endothelial Growth Factor

Introduction: Bevacizumab, a humanized antibody against VEGF, is effective within the treatment of patients with several cancers. However, like several therapeutic agents, important side effects such as arterial thromboembolism, venous thromboembolism, hypertension, neutropenia, proteinuria, and hemorrhage are related to bevacizumab. Thromboembolism is one of the leading causes of morbidity and mortality in patients with cancer. Considerations have arisen relating to the chance of venous and arterial thromboembolism with the novel antiangiogenic agent bevacizumab: a recombinant humanized monoclonal antibody to a vascular endothelial growth factor which is wide employed in cancer treatment.

scholarly journals Risk of Arterial Thromboembolism in Patients With Cancer

2017 ◽  
Vol 70 (8) ◽  
pp. 926-938 ◽  
Author(s):  
Babak B. Navi ◽  
Anne S. Reiner ◽  
Hooman Kamel ◽  
Costantino Iadecola ◽  
Peter M. Okin ◽  
...  
Keyword(s):  
Arterial Thromboembolism ◽  
Patients With Cancer

L-arginine effect on inflammatory mediators: A systematic review of randomized controlled clinical trials

2019 ◽  
pp. 1-9 ◽  
Author(s):  
Seyed Reza Mirhafez ◽  
Mitra Hariri
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Inflammatory Mediators ◽  
Randomized Clinical Trials ◽  
Randomized Controlled Clinical Trials ◽  
Patients With Cancer ◽  
Reactive Protein ◽  
Randomized Controlled ◽  
Human Adults ◽  
Factor Α

Abstract. L-arginine is an important factor in several physiological and biochemical processes. Recently, scientists studied L-arginine effect on inflammatory mediators such as C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). We conducted a systematic review on randomized controlled trials assessing L-arginine effect on inflammatory mediators. We searched data bases including Google scholar, ISI web of science, SCOPUS, and PubMed/Medline up to April 2019. Randomized clinical trials assessing the effect of L-arginine on inflammatory mediators in human adults were included. Our search retrieved eleven articles with 387 participants. Five articles were on patients with cancer and 6 articles were on adults without cancer. L-arginine was applied in enteral form in 5 articles and in oral form in 6 articles. Eight articles were on both genders, two articles were on women, and one article was on men. L-arginine could not reduce inflammatory mediators among patients with and without cancer except one article which indicated that taking L-arginine for 6 months decreased IL-6 among cardiopathic nondiabetic patients. Our results indicated that L-arginine might not be able to reduce selected inflammatory mediators, but for making a firm decision more studies are needed to be conducted with longer intervention duration, separately on male and female and with different doses of L-arginine.

Are Three Items Sufficient to Measure Sense of Coherence?

2018 ◽  
Vol 34 (4) ◽  
pp. 229-237 ◽  
Author(s):  
Francesca Chiesi ◽  
Andrea Bonacchi ◽  
Caterina Primi ◽  
Alessandro Toccafondi ◽  
Guido Miccinesi
Keyword(s):  
Sense Of Coherence ◽  
Convergent Validity ◽  
Clinical Sample ◽  
Clinical Samples ◽  
Depression Symptoms ◽  
Time Saving ◽  
Positive Role ◽  
Patients With Cancer ◽  
Measure Sense

Abstract. The present study aimed at evaluating if the three-item sense of coherence (SOC) scale developed by Lundberg and Nystrom Peck (1995) can be effectively used for research purpose in both nonclinical and clinical samples. To provide evidence that it represents adequately the measured construct we tested its validity in a nonclinical (N = 658) and clinical sample (N = 764 patients with cancer). Results obtained in the nonclinical sample attested a positive relation of SOC – as measured by the three-item SOC scale – with Antonovsky’s 13-item and 29-item SOC scales (convergent validity), and with dispositional optimism, sense of mastery, anxiety, and depression symptoms (concurrent validity). Results obtained in the clinical sample confirmed the criterion validity of the scale attesting the positive role of SOC – as measured by the three-item SOC scale – on the person’s capacity to respond to illness and treatment. The current study provides evidence that the three-item SOC scale is a valid, low-loading, and time-saving instrument for research purposes on large sample.

Sign in / Sign up

Export Citation Format

Share Document